Mastic Gum for Health & Longevity - Quick Reference Sheet

Mastic Gum for Health & Longevity

Created on 10/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Mastic gum, a Greek tree resin sold as chewing gum, powder and capsules, is a traditional stomach and mouth remedy. Its most credible use is easing recurring indigestion with no visible cause, accepted by the European medicines regulator for traditional use. Chewing it may briefly reduce dental plaque. Effects on cholesterol, blood sugar and the ulcer-causing stomach bacterium are mixed. Safety looks favorable; its value for longevity is unproven. (Full Review)

Protocol

EU traditional-use dose
0.5–1 g twice daily
Powdered mastic (1–2 g/day) for mild indigestion in adults
Functional dyspepsia trial regimen
350 mg three times daily
For 3 weeks; 1.4 g/day for 4 weeks in a later crossover trial
Chewing for oral health
Raw mastic gum after meals
As in plaque trials; amounts not standardized
Time to effect
Dyspepsia relief
3–4 weeks
When dyspepsia trials measured relief
Oral bacterial effects
Within hours
Of chewing mastic
Cholesterol & glucose
8 weeks
When changes were assessed

Benefits

Contraindications
  • Hypersensitivity to mastic (including patch-test positive to gum mastic or Mastisol)
  • Pregnant or breastfeeding women
  • Children and adolescents under 18 years (oral use)
  • Pollen hypersensitivity
Key Interactions
  • Proton pump inhibitors (acid-reducing drugs such as pantoprazole): Caution
  • Over-the-counter antacids and acid reducers (calcium carbonate, famotidine): Caution (theoretical)
  • Other chewing gums and topical adhesives containing mastic (Mastisol): Caution (theoretical)
  • H. pylori antibiotic regimens (bismuth, metronidazole): Monitor
  • Glucose-lowering drugs (sulfonylureas such as gliclazide; insulin): Monitor (theoretical)
  • Cholesterol-lowering drugs (statins such as atorvastatin): Monitor (theoretical)
  • Supplements with additive metabolic effects (berberine, red yeast rice): Monitor (theoretical)
  • Drugs metabolized by CYP1A2 (caffeine, theophylline): No interaction expected (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Allergic contact dermatitis; possible rise in central blood pressure; mild stomach discomfort
  • Speculative: Cross-reactive allergy; jaw muscle and joint strain; liver enlargement and tumor promotion in rats; untested reproductive and long-term safety

Monitoring

Marker Target Why
Total cholesterol No established target; change from own baseline Expected to change (may fall)
Fasting glucose 70–99 mg/dL Expected to change; safety check with diabetes drugs
Urea breath test for H. pylori No established target; conversion from positive to negative after a course Expected to change if used against H. pylori
ALT (liver enzyme) 7–56 U/L (varies by laboratory) Expected to change (fell in long-term use)
Home blood pressure No established target for mastic use; change from own baseline Safety check (possible small rise)

Cadence: Baseline before starting; symptom review at 2 and 4 weeks; urea breath test 4–6 weeks after an H. pylori course; lipids and fasting glucose at 8–12 weeks, then every 6–12 months; blood pressure weekly for the first month

Qualitative Assessment

  • Upper-abdominal pain, fullness, bloating and heartburn frequency
  • Bowel habit and abdominal comfort in irritable bowel syndrome or inflammatory bowel disease
  • Breath freshness and gum bleeding on brushing
  • Mouth dryness
  • Skin reactions, itching or jaw soreness